Health officials in both Russia and around the world are raising concerns over Moscow’s approval of a vaccine to be used against the SARS-CoV-2 coronavirus, despite not having finished critical Phase 3 clinical trials for the new treatment necessary to determine both the effectiveness and safety of the new inoculation.
In the mad scramble to find safe and effective drugs to treat patients suffering from COVID-19, the winners and losers amongst the litany of candidates are starting to emerge, with a previously-strong contender—hydroxychloroquine—falling from favor with the FDA, and another commonly-used drug seeing success in a major clinical trial. The
Health experts around the world are trying to unravel the puzzle as to why COVID-19 infections appear to be relatively benign in some individuals who contract the disease, while others have potentially fatal—and all too often outright deadly—reactions to the coronavirus. Toward that end, researchers are looking to the DNA
One of the few reassuring aspects of the effects of COVID-19 has been that it has a markedly mild effect on young children, with the majority of young ones that contract the disease developing only mild symptoms. But an alarming trend is being reported by medical professionals in the UK